Antibody Discovery Market

Antibody Discovery Market (5th Edition): Focus on Services and Platforms - Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    767

  • Pages
    525

  • View Count
    50618

Table Of Content

1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control

2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation

2.7. Key Market Segmentation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics

3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Structure of Antibodies
5.3. History of Antibody Development
5.4. Antibody Isotypes
5.5. Mechanism of Action of Antibodies
5.6. Classification of Antibodies
5.6.1. Monoclonal Antibodies
5.6.2. Polyclonal Antibodies
5.6.3. Bispecific Antibodies
5.7. Applications of Antibodies

5.8. Concluding Remarks

6. ANTIBODY DISCOVERY: PROCESS AND METHODS
6.1. Chapter Overview
6.2. Antibody Discovery Process
6.2.1. Target Selection and Validation
6.2.2. Hit Generation
6.2.3. Lead Selection
6.2.4. Lead Optimization
6.2.4.1. Humanization
6.2.4.2. Affinity Maturation
6.2.4.3. Fc Engineering
6.2.5. Lead Characterization
6.2.6. Candidate Selection
6.3. Antibody Discovery Methods
6.3.1. Hybridoma Technology-based Method
6.3.2. In vitro Display Method
6.3.2.1. Phage Display
6.3.2.2. Yeast Display
6.3.2.3. Ribosomal Display
6.3.3. Transgenic Animal-based Method
6.3.4. Single B Cell-based Method
6.3.5. Advantages and Disadvantages of Existing Antibody Discovery Techniques

6.4. Evolution of Monoclonal Antibodies
6.4.1. Fully Human Monoclonal Antibodies

6.5. Concluding Remarks

7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers: List of Industry Players
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Type of Antibody Discovery Services Offered
7.2.5. Analysis by Type of Antibody Discovered
7.2.6. Analysis by Type of Antibody Discovery Method
7.2.7. Analysis by Animal Model Used
7.2.8. Analysis by Type of Antibody Discovered and Type of Antibody Discovery Method
7.2.9. Analysis by Type of Antibody Discovery Services and Location of Headquarters
7.2.10. Analysis by Application Area

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Companies Grouped Grouped based on Company Size
8.4.1. Very Small Companies Offering Antibody Discovery Services
8.4.2. Small Companies Offering Antibody Discovery Services
8.4.3. Mid-sized Companies Offering Antibody Discovery Services
8.4.4. Large Companies Offering Antibody Discovery Services

8.5. Antibody Discovery Service Providers: Regional Capability
8.5.1. Antibody Discovery Service Providers based in North America
8.5.2. Antibody Discovery Service Providers based in Europe
8.5.3. Antibody Discovery Service Providers based in Asia

9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Antibody Discovery Service Providers in North America
9.2.1. Abwiz Bio
9.2.1.1. Company Overview
9.2.1.2. Recent Developments and Future Outlook

9.2.2. Abzena
9.2.2.1. Company Overview
9.2.2.2. Recent Developments and Future Outlook

9.2.3. Aragen Life Sciences
9.2.3.1. Company Overview
9.2.3.2. Recent Developments and Future Outlook

9.2.4. Capralogics
9.2.4.1. Company Overview
9.2.4.2. Recent Developments and Future Outlook

9.2.5. Creative Biolabs
9.2.5.1. Company Overview
9.2.5.2. Financial Information
9.2.5.3. Recent Developments and Future Outlook

9.2.6. DetaiBio
9.2.6.1. Company Overview
9.2.6.2. Recent Developments and Future Outlook
9.2.7. ImmunoPrecise Antibodies
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Recent Developments and Future Outlook

9.2.8. Integral Molecular
9.2.8.1. Company Overview
9.2.8.2. Recent Developments and Future Outlook

9.2.9. Syd Labs
9.2.9.1. Company Overview
9.2.9.2. Recent Developments and Future Outlook

9.3. Antibody Discovery Service Providers in Europe
9.3.1. BIOTEM
9.3.1.1. Company Overview
9.3.1.2. Recent Developments and Future Outlook

9.3.2. FairJourney Biologics
9.3.2.1. Company Overview
9.3.2.2. Recent Developments and Future Outlook

9.3.3. Fusion Antibodies
9.3.3.1. Company Overview
9.3.3.2. Recent Developments and Future Outlook

9.3.4. Proteogenix
9.3.4.1. Company Overview
9.3.4.2. Recent Developments and Future Outlook

9.3.5. RD Biotech
9.3.5.1. Company Overview
9.3.5.2. Recent Developments and Future Outlook

9.4. Antibody Discovery Service Providers in Asia
9.4.1. ABGENEX
9.4.1.1. Company Overview
9.4.1.2. Recent Developments and Future Outlook

9.4.2. ChemPartner
9.4.2.1. Company Overview
9.4.2.2. Recent Developments and Future Outlook

9.4.3. Viva Biotech
9.4.3.1. Company Overview
9.4.3.2. Financial Information
9.4.3.3. Recent Developments and Future Outlook

9.4.4. WuXi Biologics
9.4.4.1. Company Overview
9.4.4.2. Financial Information
9.4.4.3. Recent Developments and Future Outlook

10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE
10.1. Chapter Overview
10.2. Antibody Discovery: List of Technologies
10.2.1. Analysis by Type of Antibody Discovery Method
10.2.2. Analysis by Type of Antibody Discovered
10.2.3. Analysis by Animal Model Used
10.2.4. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovered
10.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters

10.3. Antibody Discovery Technologies: Developer Landscape
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Location of Headquarters
10.3.4. Most Active Players: Analysis by Number of Technologies

11. TECHNOLOGY COMPETITIVENESS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology

11.4. Antibody Discovery Technologies: Competitiveness Analysis
11.4.1. Antibody Discovery Technologies Offered by Companies based in North America
11.4.2. Antibody Discovery Technologies Offered by Companies based in Europe
11.4.3. Antibody Discovery Technologies Offered by Companies based in Asia and Rest of the World

12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS
12.1. Chapter Overview
12.2. Ablexis
12.2.1. Company Overview
12.2.2. Antibody Discovery Platform Portfolio
12.2.3. Recent Developments and Future Outlook

12.3. Creative Biolabs
12.3.1. Company Overview
12.3.2. Antibody Discovery Platform Portfolio
12.3.3. Recent Developments and Future Outlook

12.4. Genmab
12.4.1. Company Overview
12.4.2. Financial Information
12.4.3. Antibody Discovery Platform Portfolio
12.4.4. Recent Developments and Future Outlook

12.5. Harbour Biomed
12.5.1. Company Overview
12.5.2. Financial Information
12.5.3. Antibody Discovery Platform Portfolio
12.5.4. Recent Developments and Future Outlook

12.6. Immunome
12.6.1. Company Overview
12.6.2. Antibody Discovery Platform Portfolio
12.6.3. Recent Developments and Future Outlook

12.7. Isogenica
12.7.1. Company Overview
12.7.2. Antibody Discovery Platform Portfolio
12.7.3. Recent Developments and Future Outlook

12.8. Ligand Pharmaceuticals
12.8.1. Company Overview
12.8.2. Financial Information
12.8.3. Antibody Discovery Platform Portfolio
12.8.4. Recent Developments and Future Outlook

12.9. Kymab
12.9.1. Company Overview
12.9.2. Antibody Discovery Platform Portfolio
12.9.3. Recent Developments and Future Outlook

12.10. MorphoSys
12.10.1. Company Overview
12.10.2. Financial Information
12.10.3. Antibody Discovery Platform Portfolio
12.10.4. Recent Developments and Future Outlook

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year of Partnership and Type of Partner
13.3.4. Analysis by Type of Antibody
13.3.5. Most Active Players: Analysis by Number of Partnerships
13.3.6. Most Popular Technologies: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.8. Intracontinental and Intercontinental Agreements

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. Antibody Discovery Service and Platform Providers: Funding and Investment
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Type of Funding
14.3.3. Analysis of Amount Invested by Year of Funding
14.3.4. Analysis by Year-wise Number of Funding Instances and Funding Amount
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested
14.3.7. Leading Investors: Analysis by Number of Funding Instances
14.3.8. Analysis by Year-wise Number of Funding Instances and Type of Player
14.3.9. Analysis by Year-wise Amount Invested and Type of Player
14.3.10. Analysis of Number of Funding Instances by Year of Establishment and Type of Player
14.3.11. Analysis by Geography

14.4. Concluding Remarks

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview

15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges

15.6. Conclusion
16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
16.3.1. Scenario Analysis

16.4. Key Market Segmentations
16..5. Dynamic Dashboard

17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
 
17.3. Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.4. Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.5. Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.6. Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
17.7. Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

17.8. Data Triangulation and Validation

18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD
18.1. Chapter Overview
18.2. Key Assumptions and Methodology

18.3. Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.4. Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.5. Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.6. Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.7. Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
18.8. Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

18.9. Data Triangulation and Validation

19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology

19.3. Humanized: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.4. Human: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.5. Chimeric: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
19.6. Murine: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

19.7. Data Triangulation and Validation

20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology

20.3. Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.4. Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.5. Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.6. Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.7. Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
20.8. Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

20.9. Data Triangulation and Validation

21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES
21.1. Chapter Overview
21.2. Key Assumptions and Methodology

21.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.6. Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.7. Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
21.8. Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

21.9. Data Triangulation and Validation

22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
22.3.1. Scenario Analysis

22.4. Key Market Segmentations
22.5. Dynamic Dashboard

23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.4. Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
23.5. Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

23.6. Data Triangulation and Validation

24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.4. Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
24.5. Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)

24.6. Data Triangulation and Validation

25. LICENSING DEAL STRUCTURE
25.1. Chapter Overview
25.2. Key Parameters
25.3. Assumptions and Methodology
25.3.1. Overall Cash Flow for Licensee Companies
25.3.1.1. Investments Made by a Licensee
25.3.1.2. Revenues Earned by a Licensee
 
25.3.2. Overall Cash Flow for Licensor Companies
25.3.2.1. Investments Made by a Licensor
25.3.2.2. Revenues Earned by a Licensor

25.4. Key Analytical Outputs
25.4.1. Scenario 1: Variation of Upfront and Milestone Payments
25.4.2. Scenario 2: Variation of Upfront Payments and Sales-based Royalties
25.4.3. Scenario 3: Variation of Milestone Payments and Sales-based Royalties

26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS
26.1. Chapter Overview
26.2. Antibody Humanization and Affinity Maturation Service and Platform Providers: List of Players
26.3. Antibody Humanization Service Providers: SWOT Analysis
26.3.1. Strengths
26.3.2. Weaknesses
26.3.3. Opportunities
26.3.4. Threats

27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES
27.1. Chapter Overview
27.2. Humira® (Adalimumab)
27.2.1. Drug Overview
27.2.2. Discovery Process and Method
27.2.3. Historical Sales

27.3. Keytruda® (Pembrolizumab)
27.3.1. Drug Overview
27.3.2. Discovery Process and Method
27.3.3. Historical Sales

27.4. Stelara® (Ustekinumab)
27.4.1. Drug Overview
27.4.2. Discovery Process and Method
27.4.3. Historical Sales

27.5. Dupixent® (Dupilumab)
27.5.1. Drug Overview
27.5.2. Discovery Process and Method
27.5.3. Historical Sales

27.6. Opdivo® (Nivolumab)
27.6.1. Drug Overview
27.6.2. Discovery Process and Method
27.6.3. Historical Sales

28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY
28.1. Chapter Overview
28.2. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
28.3. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
28.4. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
28.5. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
28.6. Future Growth Opportunities in the Asia and Rest of the World
28.7. Expected Increase in Number of Collaborations and Licensing Activity
28.8 Concluding Remarks

29. CONCLUSION

30. EXECUTIVE INSIGHTS
30.1. Chapter Overview

30.2. Antibody Solutions
30.2.1. Company Snapshot
30.2.2. Interview Transcript

30.3. Adimab
30.3.1. Company Snapshot
30.3.3. Interview Transcript

30.4. ImmunoPrecise Antibodies
30.4.1. Company Snapshot
30.4.3. Interview Transcript

30.5. Anonymous
30.5.1. Anonymous, Chief Business Officer (Q3 2023)

30.6. Abveris, Acquired by Twist Biosciences
30.6.1. Company Snapshot
30.6.2. Interview Transcript

30.7. Nidus BioSciences
30.7.1. Company Snapshot
30.7.2. Interview Transcript

30.8. AvantGen
30.8.1. Company Snapshot
30.8.2. Interview Transcript

30.9. Single Cell Technology
30.9.1. Company Snapshot
30.9.2. Interview Transcript

30.10. Distributed Bio
30.10.1. Company Snapshot
30.10.2. Interview Transcript

30.11. AbCellera
30.11.1. Company Snapshot
30.11.2. Interview Transcript

30.12. AbGenics Life Sciences
30.12.1. Company Snapshot
30.12.2. Interview Transcript

30.13. CDI Laboratories
30.13.1. Company Snapshot
30.13.2. Interview Transcript

30.14. AP Biosciences
30.14.1. Company Snapshot
30.14.2. Interview Transcript

30.15. YUMAB
30.15.1. Company Snapshot
30.15.2. Interview Transcript

30.16. Antibody Solutions
30.16.1. Company Snapshot
30.16.2. Interview Transcript

30.17. Ligand Pharmaceuticals
30.17.1. Company Snapshot
30.17.2. Interview Transcript

30.18. LakePharma
30.18.1. Company Snapshot
30.18.2. Interview Transcript

31. APPENDIX 1: TABULATED DATA

32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape of Antibody Discovery Services
Figure 4.2 Executive Summary: Market Landscape of Antibody Discovery Technologies
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Antibody Discovery Services Market Forecast (I/ II)
Figure 4.6 Executive Summary: Antibody Discovery Services Market Forecast (I/ II)
Figure 4.7 Executive Summary: Antibody Discovery Technologies Market Forecast
Figure 5.1  Basic Structure of an Antibody
Figure 5.2  Historical Timeline of Antibody Development
Figure 5.3  Mechanism of Action of Antibodies
Figure 5.4  Applications of Antibodies
Figure 6.1  Overview of the Antibody Discovery Process
Figure 6.2  Antibody Discovery Process: Hybridoma Method
Figure 6.3 Antibody Discovery Process: Phage Display Method
Figure 6.4  Antibody Generation Using Transgenic Animals
Figure 6.5  Approved Monoclonal Antibodies: Development Trend Analysis
Figure 6.6  Approval Timeline of Fully Human Monoclonal Antibodies
Figure 6.7  Discovery Methods of Fully Human Monoclonal Antibodies
Figure 7.1  Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 7.2  Antibody Discovery Service Providers: Distribution by Company Size
Figure 7.3  Antibody Discovery Service Providers: Distribution by Location of Headquarters
Figure 7.4  Antibody Discovery Service Providers: Distribution by Type of Service Offered
Figure 7.5  Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Figure 7.6  Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 7.7  Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 7.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Figure 7.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Figure 7.10 Antibody Discovery Service Providers: Analysis by Application Area
Figure 8.1  Competitiveness Analysis: Very Small Companies Offering Antibody Discovery Services
Figure 8.2  Competitiveness Analysis: Small Companies Offering Antibody Discovery Services
Figure 8.3  Competitiveness Analysis: Mid-sized Companies Offering Antibody Discovery Services
Figure 8.4  Competitiveness Analysis: Large Companies Offering Antibody Discovery Services
Figure 8.5  Regional Capability: Benchmarking of Players based in North America
Figure 8.6  Regional Capability: Benchmarking of Players based in Europe
Figure 8.7  Regional Capability: Benchmarking of Players based in Asia
Figure 9.1  ImmunoPrecise Antibodies: Annual Revenues, FY 2017 – FY 2023 (USD Million)
Figure 9.2  Fusion Antibodies: Annual Revenues, FY 2017 – FY 2023 (EUR Million)
Figure 9.3  Viva Biotech: Annual Revenues, FY 2017 – H1 2023 (RMB Million)
Figure 9.4  WuXi Biologics: Annual Revenues, FY 2017 – H1 2023 (RMB Billion)
Figure 10.1 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Figure 10.2 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method
Figure 10.3 Antibody Discovery Technologies: Distribution by Animal Model Used
Figure 10.4 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Figure 10.5 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Figure 10.6 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Figure 10.7 Antibody Discovery Technology Providers: Distribution by Company Size
Figure 10.8 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Figure 10.9 Most Active Players: Distribution by Number of Technologies
Figure 11.1 Competitiveness Analysis: Technologies Offered by Companies based in North America
Figure 11.2 Competitiveness Analysis: Technologies Offered by Companies based in Europe
Figure 11.3 Competitiveness Analysis: Technologies Offered by Companies based in Asia and Rest of the World
Figure 12.1 Genmab: Annual Revenues, FY 2017 - H1 2023 (DKK Billion)
Figure 12.2 Harbour Biomed: Annual Revenues, FY 2018 - H1 2023 (USD Million)
Figure 12.3 Ligand Pharmaceuticals: Annual Revenues, FY 2017 - H1 2023 (USD Million)
Figure 12.4 MorphoSys: Annual Revenues, FY 2017 - H1 2023 (EUR Million)
Figure 13.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Antibody
Figure 13.5 Most Active Players: Distribution by Number of Partnerships
Figure 13.6 Most Popular Technologies: Distribution by Number of Partnerships
Figure 13.7 Partnerships and Collaborations: Distribution by Geography
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Figure 14.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 14.3 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Figure 14.4 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Figure 14.5 Most Active Players: Distribution by Number of Funding Instances
Figure 14.6 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.7 Leading Investors: Distribution by Number of Funding Instances
Figure 14.8 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Figure 14.9 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Figure 14.10 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Figure 14.11 Funding and Investment Analysis: Distribution by Geography
Figure 14.12 Funding and Investment Analysis: Concluding Remarks
Figure 15.1 Market Drivers 
Figure 15.2 Market Restrainers 
Figure 15.3 Market Opportunities
Figure 15.4 Market Challenges 
Figure 16.1 Global Antibody Discovery Services Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 16.2 Global Antibody Discovery Services Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 16.3 Global Antibody Discovery Services Market, 2023-2035, Conservative Scenario (USD Million)
Figure 17.1 Antibody Discovery Services Market for Antigen Designing: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.2 Antibody Discovery Services Market for Hit Generation: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.3 Antibody Discovery Services Market for Lead Selection: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.4 Antibody Discovery Services Market for Lead Optimization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 17.5 Antibody Discovery Services Market for Lead Characterization: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.1 Antibody Discovery Services Market for Phage Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.2 Antibody Discovery Services Market for Yeast Display: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.3 Antibody Discovery Services Market for Hybridoma Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.4 Antibody Discovery Services Market for Transgenic Animal based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.5 Antibody Discovery Services Market for Single Cell based Method: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 18.6 Antibody Discovery Services Market for Other Antibody Discovery Methods: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.1 Antibody Discovery Services Market for Humanized Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.2 Antibody Discovery Services Market for Human Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.3 Antibody Discovery Services Market for Chimeric Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 19.4 Antibody Discovery Services Market for Murine Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.1 Antibody Discovery Services Market for Oncological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.2 Antibody Discovery Services Market for Immunological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.3 Antibody Discovery Services Market for Infectious Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.4 Antibody Discovery Services Market for Neurological Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.5 Antibody Discovery Services Market for Cardiovascular Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 20.6 Antibody Discovery Services Market for Other Disorders: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.1 Antibody Discovery Services Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.2 Antibody Discovery Services Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.3 Antibody Discovery Services Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.4 Antibody Discovery Services Market in Latin America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.5 Antibody Discovery Services Market in Middle East and North Africa: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 21.6 Antibody Discovery Services Market in Rest of the World: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 22.1 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022) and Forecasted Estimates (2023-2035) (USD Million)
Figure 22.2 Global Antibody Discovery Technologies Market, 2023-2035, Optimistic Scenario (USD Million)
Figure 22.3 Global Antibody Discovery Technologies Market, 2023-2035, Conservative Scenario (USD Million)
Figure 23.1 Antibody Discovery Technologies Market for Monoclonal Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.2 Antibody Discovery Technologies Market for Bispecific Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 23.3 Antibody Discovery Technologies Market for Other Antibodies: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.1 Antibody Discovery Technologies Market in North America: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.2 Antibody Discovery Technologies Market in Europe: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 24.3 Antibody Discovery Technologies Market in Asia: Historical Trends (2017-2022) and Forecasted Estimates (2023-2035)
Figure 25.1 Licensing Agreements: Distribution of Financial Components
Figure 25.2 Technology Licensing Deal: Payment Structure
Figure 26.1 Antibody Humanization Services and Platforms: SWOT Analysis
Figure 26.2 Antibody Humanization Services and Platforms: Strengths 
Figure 26.3 Antibody Humanization Services and Platforms: Weaknesses
Figure 26.4 Antibody Humanization Services and Platforms: Opportunities
Figure 26.5 Antibody Humanization Services and Platforms: Threats 
Figure 27.1 Humira®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.2 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.3 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Figure 27.4 Dupixent®: Annual Sales, 2018-2022 (EUR Billion)
Figure 27.5 Opdivo®: Annual Sales, 2016-2022 (USD Billion)
Figure 28.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 28.2 Other Demand Areas in Antibody Discovery Domain
Figure 29.1 Conclusion: Overall Market Landscape of Antibody Discovery Service Providers
Figure 29.2 Conclusion: Overall Market Landscape of Antibody Discovery Technologies
Figure 29.3 Conclusion: Partnerships and Collaborations
Figure 29.4 Conclusion: Funding and Investment Analysis
Figure 29.5 Conclusion: Antibody Discovery Services Market Forecast (I / II)
Figure 29.6 Conclusion: Antibody Discovery Services Market Forecast (II / II)
Figure 29.7 Conclusion: Technology Licensing Deals
Figure 29.8 Conclusion: Antibody Discovery Platforms Market Forecast 

List Of Tables

Table 5.1  Antibody Isotypes: Key Features 
Table 5.2  Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 5.3  Differences Between Polyclonal and Monoclonal Antibodies
Table 7.1  Antibody Discovery Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2  Antibody Discovery Service Providers: Information on Type of Services Offered
Table 7.3  Antibody Discovery Service Providers: Information on Type of Antibody Discovered
Table 7.4  Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method
Table 7.5  Antibody Discovery Service Providers: Information on Animal Model Used
Table 7.6  Antibody Discovery Service Providers: Information on Application Area
Table 8.1  Company Competitiveness Analysis: Parameter Weightage
Table 8.2  Regional Capability Analysis: Antibody Discovery Service Providers Based in North America
Table 8.3  Regional Capability Analysis: Antibody Discovery Service Providers Based in Europe
Table 8.4  Regional Capability Analysis: Antibody Discovery Service Providers Based in Asia
Table 9.1  List of Companies Profiled
Table 9.2 Abwiz Bio: Company Snapshot
Table 9.3 Abwiz Bio: Recent Developments and Future Outlook 
Table 9.4 Aragen Bioscience: Company Snapshot
Table 9.5 Aragen Bioscience: Recent Developments and Future Outlook 
Table 9.6 Creative Biolabs: Company Snapshot
Table 9.7 Creative Biolabs: Recent Developments and Future Outlook 
Table 9.8  Distributed Bio: Company Snapshot
Table 9.9  Distributed Bio: Recent Developments and Future Outlook 
Table 9.10 ImmunoPrecise Antibodies: Company Snapshot
Table 9.11 ImmunoPrecise Antibodies: Recent Developments and Future Outlook 
Table 9.12 Integral Molecular: Company Snapshot
Table 9.13  Integral Molecular: Recent Developments and Future Outlook 
Table 9.14  LakePharma: Company Snapshot
Table 9.15  LakePharma: Recent Developments and Future Outlook
Table 9.16 Abzena: Company Snapshot
Table 9.17  Abzena: Recent Developments and Future Outlook
Table 9.18  BIOTEM: Company Snapshot
Table 9.19  BIOTEM: Recent Developments and Future Outlook
Table 9.20  PX'Therapeutics: Company Snapshot
Table 9.21 PX'Therapeutics: Recent Developments and Future Outlook
Table 9.22  ChemPartner: Company Snapshot
Table 9.23  ChemPartner: Recent Developments and Future Outlook
Table 9.24 Viva Biotech: Company Snapshot
Table 9.25 Viva Biotech: Recent Developments and Future Outlook
Table 9.26  WuXi Biologics: Company Snapshot
Table 9.27  WuXi Biologics: Recent Developments and Future Outlook
Table 10.1  Antibody Discovery Technologies: Information on Type of Antibody Discovered
Table 10.2  Antibody Discovery Service Technologies: Information on Type of Antibody Discovery Method
Table 10.3  Antibody Discovery Service Technologies: Information on Animal Model Used
Table 10.4  Antibody Discovery Service Technologies: Information on Location of Headquarters of Developer
Table 10.5  Antibody Discovery Platform Providers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 11.1 Technology Competitiveness Analysis: Parameter Weightage
Table 12.1  List of Companies Profiled
Table 12.2 Ablexis: Company Snapshot
Table 12.3 Ablexis: Antibody Discovery Platform Portfolio
Table 12.4 Ablexis: Recent Developments and Future Outlook
Table 12.5 Creative Biolabs: Company Snapshot
Table 12.6 Creative Biolabs: Antibody Discovery Platform Portfolio
Table 12.7 Creative Biolabs: Recent Developments and Future Outlook
Table 12.8 Genmab: Company Snapshot
Table 12.9 Genmab: Antibody Discovery Platform Portfolio
Table 12.10 Genmab: Recent Developments and Future Outlook
Table 12.11 Harbour BioMed: Company Snapshot 
Table 12.12 Harbour BioMed: Antibody Discovery Platform Portfolio
Table 12.13 Harbour BioMed: Recent Developments and Future Outlook
Table 12.14 Immunome: Company Snapshot 
Table 12.15 Immunome: Antibody Discovery Platform Portfolio
Table 12.16 Immunome: Recent Developments and Future Outlook
Table 12.17 Isogenica: Company Snapshot 
Table 12.18 Isogenica: Antibody Discovery Platform Portfolio
Table 12.19 Isogenica: Recent Developments and Future Outlook
Table 12.20 Kymab: Company Snapshot 
Table 12.21 Kymab: Antibody Discovery Platform Portfolio
Table 12.22 Kymab: Recent Developments and Future Outlook
Table 12.23 Ligand Pharmaceuticals: Company Snapshot
Table 12.24 Ligand Pharmaceuticals: Antibody Discovery Platform Portfolio
Table 12.25 Ligand Pharmaceuticals: Recent Developments and Future Outlook
Table 12.26 MorphoSys: Company Snapshot 
Table 12.27 MorphoSys: Antibody Discovery Platform Portfolio
Table 12.28 MorphoSys: Recent Developments and Future Outlook
Table 13.1  Antibody Discovery Service and Platform Providers: List of Partnerships and Collaboration, 2015-2023
Table 14.1  Antibody Discovery Service and Platform Providers: List of Funding Instances, 2016-2023
Table 24.1 Developmental / Regulatory Milestones
Table 24.2  Antibody Discovery Platforms: Average Upfront and Average Milestone Payments (USD Million)
Table 25.1  Approved Monoclonal Antibodies: Information on Affinity
Table 25.2  Antibody Humanization: List of Service Providers
Table 26.1  List of Top Ten Selling Therapeutic Antibodies, 2022
Table 30.1  Antibody Solutions: Company Snapshot
Table 30.2 Adimab: Company Snapshot 
Table 30.3 ImmunoPrecise Antibodies: Company Snapshot
Table 30.4 Abveris Antibody: Company Snapshot 
Table 30.5 Nidus BioSciences: Company Snapshot 
Table 30.6 AvantGen: Company Snapshot 
Table 30.7 Single Cell Technology: Company Snapshot 
Table 30.8 Distributed Bio: Company Snapshot 
Table 30.9  AbCellera: Company Snapshot
Table 30.10 AbGenics Life Sciences: Company Snapshot
Table 30.11 CDI Laboratories: Company Snapshot 
Table 30.12 AP Biosciences: Company Snapshot 
Table 30.13 YUMAB: Company Snapshot 
Table 30.14 Antibody Solutions: Company Snapshot
Table 30.15 Ligand Pharmaceuticals: Company Snapshot
Table 30.16. LakePharma: Company Snapshot 
Table 31.1  Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 31.2  Antibody Discovery Service Providers: Distribution by Company Size
Table 31.3  Antibody Discovery Service Providers: Distribution by Location of Headquarters
Table 31.4  Antibody Discovery Service Providers: Distribution by Type of Service Offered
Table 31.5  Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered
Table 31.6  Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Table 31.7  Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 31.8 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovered and Type of Antibody Discovery Method
Table 31.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Services and Location of Headquarters
Table 31.10  Antibody Discovery Service Providers: Analysis by Application Area
Table 31.11 ImmunoPrecise Antibodies: Annual Revenues, 2016-2022 (USD Million)
Table 31.12 Fusion Antibodies: Annual Revenues, 2017-2022 (EUR Million)
Table 31.13 Viva Biotech: Annual Revenues, 2016-2022 (RMB Million)
Table 31.14 WuXi Biologics: Annual Revenues, 2016-2022 (RMB Billion)
Table 31.15 Antibody Discovery Technologies: Distribution by Type of Antibody Discovered
Table 31.16 Antibody Discovery Technologies: Distribution by Animal Model Used
Table 31.17 Antibody Discovery Technologies: Distribution by Type of Antibody Discovery Method and Location of Headquarters
Table 31.18 Antibody Discovery Technologies: Distribution by Discovery Method and Type of Antibody Discovered
Table 31.19 Antibody Discovery Technology Providers: Distribution by Year of Establishment
Table 31.20 Antibody Discovery Technology Providers: Distribution by Company Size
Table 31.21 Antibody Discovery Technology Providers: Distribution by Location of Headquarters
Table 31.22 Most Active Players: Distribution by Number of Technologies
Table 31.23 Genmab: Annual Revenues, FY 2017 – H1 2023 (DEK Billion)
Table 31.24 Harbour Biomed: Annual Revenues, FY 2018 - H1 2023 (USD Million)
Table 31.25 Ligand Pharmaceuticals: Annual Revenues, FY 2017 – H1 2023 (USD Million)
Table 31.26 MorphoSys: Annual Revenues, FY 2017 – H1 2023 (EUR Million)
Table 31.27 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2023
Table 31.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 31.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2021-2023
Table 31.30 Partnerships and Collaborations: Distribution by Type of Antibody
Table 31.31 Most Active Players: Distribution by Number of Partnerships
Table 31.32 Most Popular Technologies: Distribution by Number of Partnerships
Table 31.33 Partnerships and Collaborations: Distribution by Geography
Table 31.34 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 31.35 Funding and Investment Analysis: Cumulative Year-wise Trend, 2016-2023
Table 31.36 Funding and Investment Analysis: Distribution by Type of Funding
Table 31.37 Funding and Investment Analysis: Distribution of Amount Invested by Year of Funding, 2016-2023 (USD Million)
Table 31.38 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Funding Amount, 2016-2023 (USD Million)
Table 31.39 Most Active Players: Distribution by Number of Funding Instances
Table 31.40 Most Active Players: Distribution by Amount Invested (USD Million)
Table 31.41 Leading Investors: Distribution by Number of Funding Instances
Table 31.42 Funding and Investment Analysis: Distribution by Year-wise Number of Funding Instances and Type of Player
Table 31.43 Funding and Investment Analysis: Distribution by Year-wise Amount Invested and Type of Player
Table 31.44 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Establishment and Type of Player
Table 31.45 Funding and Investment Analysis: Distribution by Geography
Table 31.46 Global Antibody Discovery Services Market, Historical Trends, 2017-2022 (USD Million)
Table 31.47 Global Antibody Discovery Services Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 31.48 Antibody Discovery Services Market for Antigen Designing, Historical Trends 2017-2022 (USD Million)
Table 31.49 Antibody Discovery Services Market for Antigen Designing, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.50 Antibody Discovery Services Market for Hit Generation, Historical Trends, 2017-2022 (USD Million)
Table 31.51 Antibody Discovery Services Market for Hit Generation, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.52 Antibody Discovery Services Market for Lead Selection, Historical Trends, 2017-2022 (USD Million)
Table 31.53 Antibody Discovery Services Market for Lead Selection, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.54 Antibody Discovery Services Market for Lead Optimization, Historical Trends, 2017-2022 (USD Million)
Table 31.55 Antibody Discovery Services Market for Lead Optimization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.56 Antibody Discovery Services Market for Lead Characterization, Historical Trends, 2017-2022 (USD Million)
Table 31.57 Antibody Discovery Services Market for Lead Characterization, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.58 Antibody Discovery Services Market for Phage Display, Historical Trends, 2017-2022 (USD Million)
Table 31.59 Antibody Discovery Services Market for Phage Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.60 Antibody Discovery Services Market for Yeast Display, Historical Trends, 2017-2022 (USD Million)
Table 31.61 Antibody Discovery Services Market for Yeast Display, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.62 Antibody Discovery Services Market for Hybridoma Method, Historical Trends, 2017-2022 (USD Million)
Table 31.63 Antibody Discovery Services Market for Hybridoma Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.64 Antibody Discovery Services Market for Transgenic Animal based Method, Historical Trends, 2017-2022 (USD Million)
Table 31.65 Antibody Discovery Services Market for Transgenic Animal based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.66 Antibody Discovery Services Market for Single Cell based Method, Historical Trends, 2017-2022 (USD Million)
Table 31.67 Antibody Discovery Services Market for Single Cell based Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.68 Antibody Discovery Services Market for Other Antibody Discovery Method, Historical Trends, 2017-2022 (USD Million)
Table 31.69 Antibody Discovery Services Market for Other Antibody Discovery Method, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.70 Antibody Discovery Services Market for Humanized Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.71 Antibody Discovery Services Market for Humanized Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.72 Antibody Discovery Services Market for Human Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.73 Antibody Discovery Services Market for Human Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.74 Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.75 Antibody Discovery Services Market for Chimeric Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.76 Antibody Discovery Services Market for Murine Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.77 Antibody Discovery Services Market for Murine Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.78 Antibody Discovery Services Market for Oncological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.79 Antibody Discovery Services Market for Oncological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.80 Antibody Discovery Services Market for Immunological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.81 Antibody Discovery Services Market for Immunological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.82 Antibody Discovery Services Market for Infectious Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.83 Antibody Discovery Services Market for Infectious Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.84 Antibody Discovery Services Market for Neurological Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.85 Antibody Discovery Services Market for Neurological Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.86 Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.87 Antibody Discovery Services Market for Cardiovascular Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.88 Antibody Discovery Services Market for Other Disorders, Historical Trends, 2017-2022 (USD Million)
Table 31.89 Antibody Discovery Services Market for Other Disorders, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.90 Antibody Discovery Services Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 31.91 Antibody Discovery Services Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.92 Antibody Discovery Services Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 31.93 Antibody Discovery Services Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.94 Antibody Discovery Services Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 31.95 Antibody Discovery Services Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.96 Antibody Discovery Services Market in Latin America, Historical Trends, 2017-2022 (USD Million)
Table 31.97 Antibody Discovery Services Market in Latin America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.98 Antibody Discovery Services Market in Middle East and North Africa, Historical Trends, 2017-2022 (USD Million)
Table 31.99 Antibody Discovery Services Market in Middle East and North Africa, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.100 Antibody Discovery Services Market in Rest of the World, Historical Trends, 2017-2022 (USD Million)
Table 31.101 Antibody Discovery Services Market in Rest of the World, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.102 Global Antibody Discovery Technologies Market, Historical Trends (2017-2022)
Table 31.103 Global Antibody Discovery Technologies Market, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.104 Antibody Discovery Technologies Market for Monoclonal Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.105 Antibody Discovery Technologies Market for Monoclonal Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.106 Antibody Discovery Technologies Market for Bispecific Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.107 Antibody Discovery Technologies Market for Bispecific Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.108 Antibody Discovery Technologies Market for Other Antibodies, Historical Trends, 2017-2022 (USD Million)
Table 31.109 Antibody Discovery Technologies Market for Other Antibodies, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.110 Antibody Discovery Technologies Market in North America, Historical Trends, 2017-2022 (USD Million)
Table 31.111 Antibody Discovery Technologies Market in North America, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.112 Antibody Discovery Technologies Market in Europe, Historical Trends, 2017-2022 (USD Million)
Table 31.113 Antibody Discovery Technologies Market in Europe, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.114 Antibody Discovery Technologies Market in Asia, Historical Trends, 2017-2022 (USD Million)
Table 31.115 Antibody Discovery Technologies Market in Asia, Forecasted Estimates, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 31.116 Humira®: Annual Sales, 2016-2022 (USD Billion)
Table 31.117 Keytruda®: Annual Sales, 2016-2022 (USD Billion)
Table 31.118 Stelara®: Annual Sales, 2016-2022 (USD Billion)
Table 31.119 Dupixent®: Annual Sales, 2018-2022 (EUR Billion)
Table 31.120 Opdivo®: Annual Sales, 2016-2022 (USD Million)

List Of Companies

  1. 2BScientific
  2. 3SBio
  3. AAT Bioquest
  4. Ab Initio Biotherapeutics
  5. Ab Studio
  6. ABBA Therapeutics
  7. AbBioSci
  8. Abbiotec
  9. AbbVie
  10. Abcalis
  11. Abcam
  12. AbCellera
  13. Abcentra (formerly CardioVax)
  14. Abcepta
  15. AbCheck
  16. Abclonal
  17. Abcore
  18. ABDYS
  19. Abeome
  20. Abexxa Biologics
  21. ABGENEX
  22. AbGenics Life Sciences
  23. Abilita Bio
  24. ABL Bio
  25. Ablexis
  26. Ablynx
  27. Abnova
  28. Abpro
  29. AbSano
  30. Absci
  31. Absea Biotechnology
  32. Absolute Antibody
  33. Abterra Biosciences
  34. AbTherx
  35. AbTis
  36. Abveris (Acquired by Twist Bioscience)
  37. AbVision
  38. Abwiz Bio
  39. Abzena
  40. Abzyme Therapeutics
  41. AC Immune
  42. Acceleron Pharma
  43. Accurus Biosciences
  44. AceMab
  45. Achaogen
  46. Aclys Bio
  47. ACROBiosystems
  48. ACYTE Biotech
  49. Adagene
  50. Adaptate Biotherapeutics
  51. ADC Therapeutics
  52. Adcentrx Therapeutics
  53. Adimab
  54. AdipoGen Life Sciences
  55. Administration for Strategic Preparedness and Response (ASPR)
  56. Aduro Biotech
  57. AffinityImmuno
  58. AFSBio
  59. Aganitha
  60. Agency for Science, Technology and Research
  61. Agenus
  62. Agro-Bio
  63. AIMM Therapeutics
  64. Aimmune Therapeutics
  65. Akeagen
  66. Akeso
  67. Akeso Biopharma
  68. Alacrita
  69. Alamar Biosciences
  70. Aldevron
  71. Alector
  72. Alexion
  73. AlivaMab Discovery Services
  74. Alligator Bioscience
  75. Allogene Therapeutics
  76. Alloy Therapeutics
  77. Almirall
  78. AlpalifeBio
  79. ALSA Ventures
  80. Alvaxa Biosciences (Acquired by Sensei Biotherapeutics)
  81. ALX Oncology
  82. Alytas Therapeutics
  83. Amerigo Scientific
  84. Amgen
  85. AMSBIO
  86. Analytics Engine
  87. AnaptysBio
  88. Angios
  89. Annoron Biotechnology
  90. Antengene
  91. Antibodies Incorporated
  92. Antibodies-online
  93. Antibody Analytics
  94. Antibody Design Labs
  95. Antibody Production Services (A division of Life Science Group)
  96. Antibody Solutions
  97. Antiverse
  98. AP Biosciences
  99. Apexigen
  100. APITBIO
  101. Applied Biological Materials
  102. Applied StemCell
  103. AprilBio
  104. Aptevo Therapeutics
  105. Aragen Life Sciences
  106. Aravive
  107. Arctoris
  108. Arcus Biosciences
  109. argenx
  110. Aridis Pharmaceuticals
  111. aRNAy Sciences
  112. Aro Biotherapeutics
  113. Aronora
  114. Arsanis
  115. Artizan Biosciences
  116. Arvinas
  117. ARVYS Proteins
  118. AskGene Pharma
  119. Astellas
  120. AstraZeneca
  121. aTen Therapeutics
  122. Atlantis Bioscience
  123. Atlas Venture
  124. Atreca
  125. ATUM
  126. Aureka
  127. Aurigene Pharmaceutical Services
  128. Autolus Therapeutics
  129. Automated Lab Solutions
  130. AvantGen
  131. Aviva Systems Biology
  132. AxioMx
  133. Axxora
  134. Bayer
  135. BBI Group
  136. BBI Solutions
  137. Beckman Coulter
  138. BeiGene
  139. BenevolentAI
  140. Berkeley Lights
  141. Betta Pharmaceuticals
  142. Bhami's Research Laboratories
  143. Bhat Bio-tech India
  144. Big Cypress Acquisition
  145. BigHat Biosciences
  146. Bill & Melinda Gates Foundation
  147. Bill & Melinda Gates Medical Research Institute
  148. Bio Bench
  149. BioArctic
  150. BioAtla
  151. BioBench Solutions
  152. Biochem Pharma
  153. BioClue (Acquired by ImmunoPrecise Antibodies)
  154. Bio-Connect
  155. Biocure Technology
  156. Biocytogen
  157. BioD
  158. BioDuro-Sundia
  159. Biogen
  160. BioHub International Trade
  161. Bioinborn Scientific
  162. Biointron
  163. BioInvent
  164. BioKey (Acquired by ImmunoPrecise Antibodies)
  165. Biologics International
  166. Biomolecular Discovery Services
  167. BioNTech
  168. Bioqube Ventures
  169. Bio-Rad Laboratories
  170. Biosion
  171. BioStrand (Acquired by ImmunoPrecise Antibodies)
  172. Biosynth
  173. Biotalys
  174. Bio-Techne
  175. Biotecnol
  176. BIOTEM
  177. BioTeZ
  178. Biotheus
  179. BioTickle
  180. BioVision
  181. BioXpress Therapeutics
  182. Bird Rock Bio
  183. Blue Sky BioServices (Acquired by LakePharma)
  184. BlueBird Bio
  185. Bluejay Therapeutics
  186. Boan Biotech
  187. Boehringer Ingelheim
  188. Bolt Biotherapeutics
  189. Boster Biological Technology
  190. Bristol Myers Squibb
  191. Broteio Pharma
  192. CALIXAR
  193. Cambridge Research Biochemicals
  194. CANbridge Pharmaceuticals
  195. Cancer Research UK
  196. Cantargia
  197. Capra Science
  198. Capralogics
  199. Caris Life Sciences
  200. Carterra
  201. CASI Pharmaceuticals
  202. Catalent Biologics
  203. Cayman Chemical
  204. CD ComputaBio
  205. CDI Laboratories
  206. Celexion
  207. Celgene
  208. Cell Signaling Technology
  209. Celltrion
  210. Celros Biotech
  211. Celsius Therapeutics
  212. Centre for Applied Medical Research
  213. Centers for Disease Control and Prevention
  214. Charles River
  215. ChemBio Discovery Solutions
  216. ChemPartner
  217. Cherry Biolabs 
  218. Chia Tai Tianqing Pharmaceutical
  219. Chiome Bioscience
  220. Chipscreen Biosciences
  221. ChromoTek
  222. Chugai Pharmabody Research
  223. Chugai Pharmaceutical
  224. Cidara Therapeutics
  225. Cilag
  226. Citryll
  227. City of Hope
  228. Cizzle Biotechnology
  229. Clayton Biotechnologies
  230. Click Chemistry Tools
  231. Clínica Universidad de Navarra
  232. CliniSciences
  233. Columbia University Irving Medical Center
  234. Compass Therapeutics
  235. Context Therapeutics
  236. Coronavirus Immunotherapy Consortium
  237. Corvidia Therapeutics
  238. Cosmo Bio
  239. CP Qingdao
  240. Creative Bioarray
  241. Creative Biolabs
  242. Creative Biostructure
  243. Creative Diagnostics
  244. Crescendo Biologics
  245. Crystal Bioscience
  246. CSL Behring
  247. Cstone Pharmaceuticals
  248. CureVac
  249. Curia
  250. CUSABIO
  251. Cyclogenix
  252. Cygnus Technologies
  253. DAAN Biotherapeutics
  254. Daiichi Sankyo
  255. Dako
  256. Dana-Farber Cancer Institute
  257. Danaher
  258. DaTaMabs
  259. DBA Italia
  260. Deerfield Discovery and Development
  261. Denali Therapeutics
  262. DetaiBio
  263. Diagnostic BioSystems
  264. Diatheva
  265. Digital Proteomics
  266. Dingkang Biology
  267. discoveric bio
  268. Distributed Bio
  269. DJS Antibodies
  270. Dragonfly Therapeutics
  271. E2DG
  272. Eisai
  273. Elabscience
  274. Eli Lilly and Company
  275. Elpis Biopharmaceuticals
  276. Emergent BioSolutions
  277. Empirico
  278. e-nnovation Life Sciences
  279. ENPICOM
  280. Enthera
  281. Entos Pharmaceuticals
  282. Envigo
  283. EpimAb Biotherapeutics
  284. EQRx
  285. Erasmus MC
  286. Ethris
  287. Eureka Therapeutics
  288. Eurofins Discovery
  289. Everest Medicines
  290. Evitria
  291. Evotec
  292. EVQLV
  293. Exelixis
  294. ExeVir Bio
  295. Exiris
  296. exonbio
  297. Exscientia
  298. Faculta (Acquired by Prosci)
  299. FairJourney Biologics
  300. Faron Pharmaceuticals
  301. Ferring Pharmaceuticals
  302. FibroGen
  303. Five Prime Therapeutics
  304. Fluoroprobes
  305. Forty Seven
  306. Foundery Innovations
  307. Fred Hutchinson Cancer Center
  308. Frederick National Laboratory for Cancer Research
  309. French Institute of Health and Medical Research
  310. Frugi Biotechnology
  311. Funakoshi
  312. Fusion Antibodies
  313. Fusion Pharmaceuticals
  314. G&P Biosciences
  315. G.CLIPS BIOTECH
  316. Gator Bio
  317. Genagon Therapeutics
  318. Gene Techno Science
  319. GeneBeyond
  320. Genedata
  321. GeneFrontier 
  322. GENEWIZ (Acquired by Azenta Life Sciences)
  323. GeneX India Bioscience
  324. Genmab
  325. Genome Institute of Singapore
  326. Genor Biopharma
  327. GenoSafe
  328. Genovac
  329. GenScript
  330. Genuv
  331. Gen-Y Biologics
  332. GigaGen
  333. Gilead Sciences
  334. Gladstone Institutes
  335. Glenmark Pharmaceuticals
  336. Glythera
  337. Gmax Biopharm
  338. Government of British Columbia
  339. Government of Canada
  340. Green Mountain Antibodies
  341. Grenoble Hospital
  342. GSK
  343. Gustave Roussy
  344. GV20 Therapeutics
  345. HaemaLogiX
  346. Hangzhou Qiantang River Electric
  347. Harbour Antibodies
  348. Harbour BioMed
  349. Harpoon Therapeutics
  350. HD Biosciences
  351. Helix BioPharma
  352. Jiangsu Hengrui Pharmaceuticals
  353. Henlix Biotech
  354. Heptares Therapeutics
  355. HI-Bio
  356. HiFiBiO Therapeutics
  357. Himalaya Therapeutics
  358. H-Immune Therapeutics (Acquired by HiFiBiO Therapeutics)
  359. HJB
  360. Hölzel Diagnostika Handels
  361. Horizon Discovery
  362. Hualan Genetic Engineering
  363. Hubrecht Institute
  364. Humanigen
  365. Hummingbird Bioscience
  366. I&L Biosystems
  367. i2 Pharmaceuticals
  368. IAMA France
  369. IASO Biotherapeutics
  370. Ibex Biosciences
  371. iBio
  372. Icagen
  373. Icosagen
  374. IGEM Therapeutics
  375. IgGenix
  376. IGM Biosciences
  377. I-Mab Biopharma
  378. iMetabolic Biopharma
  379. Immatics Biotechnologies
  380. Immorna
  381. Immune Biosolutions
  382. Immune Pharmaceuticals
  383. Immunitas Therapeutics
  384. immunitoAI
  385. Immunochem
  386. ImmunoChina Pharmaceuticals
  387. ImmunoGenes
  388. Immunome
  389. Immunomic Therapeutics
  390. ImmunoPrecise Antibodies
  391. ImmunoQure
  392. Immusmol
  393. Immutep
  394. In-Cell-Art
  395. Incyte
  396. Indivumed
  397. InflaRx
  398. Inhibrx
  399. Innate Pharma
  400. InnoBation Bio
  401. Innovagen
  402. Innovative Targeting Solutions
  403. Innovent
  404. Inotiv
  405. InstaDeep
  406. Institute for Research in Biomedicine
  407. Intarcia Therapeutics (Acquired by i2o Therapeutics)
  408. Integral Molecular
  409. Integrated DNA Technologies
  410. International Livestock Research Institute
  411. Invenra
  412. Invetx
  413. IONTAS
  414. IRBM
  415. Isogenica
  416. Italian National Institute of Health
  417. ITBMed
  418. iTeos Therapeutics
  419. Janssen
  420. Jazz Pharmaceuticals
  421. Johnson & Johnson Innovation
  422. Jotbody
  423. Jounce Therapeutics
  424. Juno Therapeutics
  425. Junshi Biosciences
  426. Just Biotherapeutics
  427. JW Pharmaceuticals
  428. Kadmon
  429. Kairos Therapeutics
  430. KAKEN PHARMACEUTICAL
  431. Kanwhish Biotechnology
  432. KareBay Biochem
  433. Karolinska University Hospital
  434. Kemp Proteins
  435. KGbio
  436. Kite Pharma
  437. KMD Bioscience
  438. Kodiak Sciences
  439. KYinno
  440. Kymab
  441. Kyoritsuseiyaku
  442. Kyowa Kirin
  443. La Jolla Institute for Immunology
  444. LabGenius
  445. Labtoo
  446. LakePharma
  447. LamKap Bio
  448. LAMPIRE Biological Labs
  449. Lanier Biotherapeutics
  450. Lava Therapeutics
  451. Leadgene Biomedical
  452. Leading Biology
  453. Leads Biolabs
  454. LegoChem Biosciences
  455. Leica Microsystems
  456. LEO Pharma
  457. LG Chem
  458. LifeArc
  459. LifeTein
  460. Ligand Pharmaceuticals
  461. Light Chain Bioscience
  462. Lineage Cell Therapeutics
  463. Lonza
  464. Loxo Oncology
  465. Lunaphore
  466. Lundbeck
  467. Luye Pharma
  468. MAB Discovery
  469. MabGenesis
  470. Mablytics
  471. Mabpharm
  472. MAbSilico
  473. mAbsolve
  474. MabSpace Biosciences
  475. Mabtech
  476. MabVax
  477. Mabworks
  478. MacroGenics
  479. Magenta Therapeutics
  480. Maine Biotechnology Services
  481. Maravai LifeSciences
  482. Masaachusetts General Hospital
  483. Mass Biologics
  484. Maverick Therapeutics
  485. Beijing Mede Taikang Biotechnology 
  486. MedAbome
  487. MedGenome
  488. Medicilon
  489. MedImmune
  490. Medix Biochemica
  491. MEDx
  492. MEMO Therapeutics
  493. Memorial Sloan Kettering Cancer Center
  494. Merck
  495. Merus
  496. Mila
  497. MI-mAbs
  498. Mithra Pharmaceuticals
  499. Mitsubishi Tanabe Pharma Corporation
  500. Moderna
  501. ModeX Therapeutics
  502. ModiQuest
  503. Molcure
  504. Molecular Devices
  505. Molecular Templates
  506. MolMed
  507. Mologic
  508. Moradec
  509. MorphoSys
  510. Mount Sinai
  511. MSD
  512. MSM Protein Technologies
  513. Mycenax Biotech
  514. Myrio Therapeutics
  515. Mythic Therapeutics
  516. Nanjing Chia-Tai Tianqing Pharmaceutical Company
  517. Nanocarry Therapeutics
  518. NanoCellect Biomedical
  519. NanoString Technologies
  520. National Cancer Institute
  521. National Research Council of Canada's Human Health Therapeutics Research Centre
  522. National, Heart, Lung, and Blood Institute
  523. NaturalAntibody
  524. Nautilus Systems
  525. NB Health Laboratory
  526. NBE Therapeutics
  527. Nelum
  528. NeoBiotechnologies
  529. NeoClone
  530. Neon Therapeutics
  531. neoX Biotech
  532. Neurimmune
  533. Nexum
  534. Nidus MB Technologies
  535. Nidus BioSciences
  536. Nkarta
  537. Nona BioSciences
  538. Nordic Society of Gynaecological Oncology
  539. Normunity
  540. North Dakota State University
  541. Northway Biotech
  542. NovaRock Biotherapeutics
  543. Novartis
  544. Novo Holdings
  545. Novo Nordisk
  546. Numab Therapeutics
  547. NYU Langone Health
  548. Oak BioSciences
  549. Oblique Therapeutics
  550. Olympic Protein Technologies
  551. OmniAb
  552. OncoC4
  553. OncoOne
  554. OncoResponse
  555. Oncothyreon
  556. Onena Medicines
  557. Ono Pharmaceuticals
  558. Open Monoclonal Technology
  559. Optimeos Life Sciences
  560. OREGA Biotech
  561. OriCell
  562. OriGene Technologies
  563. OriMAbs
  564. Orion
  565. OSE Immunotherapeutics
  566. Ossianix
  567. Oxford Biomedica
  568. OXGENE
  569. Pandion Therapeutics
  570. Panoply Bio
  571. Paragon Therapeutics
  572. Pascal Biosciences
  573. Pediatric Brain Tumor Consortium 
  574. Penn Medicine
  575. PerkinElmer
  576. Perseus Proteomics
  577. Pfizer
  578. pH Pharma
  579. Phanes Therapeutics
  580. PharmAbcine
  581. PharmAbs
  582. PharmaEssentia Innovation Research Center
  583. PharmaLegacy
  584. Pharmsynthez
  585. Pierre Fabre
  586. Pinteon Therapeutics
  587. Pioneering Medicines
  588. Pionyr Immunotherapeutics
  589. Potenza Therapeutics
  590. Precision Antibody
  591. Prellis Biologics
  592. ProMab Biotechnologies
  593. Prometheus Authors
  594. Prosci
  595. Protein Alternatives
  596. Proteogenix
  597. ProteoNic
  598. ProtTech
  599. Purdue Pharma
  600. Pure Biologics
  601. PX'Therapeutics
  602. QIMR Berghofer Medical Research Institute
  603. QoolAbs
  604. Quadira Biosciences
  605. Queen's University
  606. Rallybio
  607. Rapid Novor
  608. RayBiotech
  609. RD Biotech
  610. ReCentrics Biotechnology
  611. Regeneron Pharmaceuticals
  612. Resonant Therapeutics
  613. Retrogenix
  614. RevMab Biosciences
  615. Revolve Biotechnologies
  616. Rezolute
  617. Roche
  618. Rockland Immunochemicals
  619. RubrYc Therapeutics
  620. Rx Biosciences
  621. RxBiologics
  622. SAb Biotherapeutics
  623. Saccharo
  624. Salipro Biotech
  625. San Diego Biomedical Research Institute
  626. Sanders Tri-Institutional Therapeutics Discovery Institute
  627. Sanofi
  628. Sanyou Biopharmaceuticals
  629. Sartorius
  630. SBH Sciences
  631. Scandion Oncology
  632. Scotia Biologics
  633. Sea Lane Biotechnologies
  634. Selecxine
  635. Sema4
  636. Sensei Biotherapeutics
  637. Serum Institute of India
  638. Servier
  639. Severance Hospital
  640. Sevion Therapeutics
  641. Shanghai Henlius Biotech
  642. Shanghai KangaBio
  643. Shanghai Pidu Biotechnology
  644. Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry RAS
  645. Shire
  646. Sichuan Kelun-Biotech Biopharmaceutical
  647. Siegfried Holding
  648. Simcere
  649. Simon Fraser University
  650. Single Cell Technology
  651. Sino Biological
  652. Sinobioway
  653. Sinopharm
  654. SmartPharm Therapeutics
  655. Sorrento Therapeutics
  656. SOTIO
  657. SouthernBiotech
  658. Specialised Therapeutics
  659. Specifica 
  660. Sphere Fluidics
  661. Stanford University
  662. Straterx
  663. Summit Therapeutics
  664. Sunshine Guojian
  665. Surface Oncology
  666. Surrozen
  667. Sutro Biopharma
  668. Suzhou Bright Scistar Biotechnology Company
  669. Syd Labs
  670. Symphogen
  671. Synaffix
  672. Synbio Technologies
  673. Syngene
  674. Synthelis
  675. Tachyon Therapeutics
  676. Takeda
  677. Tanabe Research Laboratories
  678. Tasgen Biotech (Acquried by I-Mab Biopharma)
  679. Tasly Biopharmaceuticals
  680. Taurus Biosciences
  681. TC BioPharm
  682. Technical University of Denmark
  683. Telesis Bio
  684. Telix Pharmaceuticals
  685. Tempus Labs
  686. TeneoBio
  687. TESARO
  688. Tetra Partner Network
  689. Tetragenetics
  690. Teva Pharmaceuticals
  691. TG Therapeutics
  692. The Antibody Company
  693. The Wistar Institute
  694. Theraclone Sciences
  695. Theranyx
  696. ThermoFisher Scientific
  697. Third Venture Biopharma
  698. ThromboGenics
  699. Tizona Therapeutics
  700. Tmunity Therapeutics
  701. Torch Biosciences
  702. TRACON Pharmaceuticals
  703. TRANSCENTA
  704. Transgene
  705. TRIANNI
  706. Tsinghua University
  707. Tubulis
  708. Twist Bioscience
  709. U.S. Naval Medical Research Unit No. 3
  710. UCLA Technology Development Group
  711. Universiti Sains Malaysia
  712. University College London
  713. University of Manchester
  714. University of Oxford
  715. University of Pennsylvania
  716. University of Southampton
  717. University of Surrey
  718. University of Texas MD Anderson Cancer Center
  719. University of Tokyo
  720. University of Zurich
  721. U-Protein (Acquired by ImmunoPrecise Antibodies)
  722. Utrecht University
  723. Vaccinex
  724. ValenzaBio (Acquired by ACELYRIN)
  725. Vall d’Hebron Institute of Oncology
  726. Valneva
  727. VBI Vaccines
  728. VectorB2B
  729. venBio Partners
  730. VERAXA Biotech
  731. Vir Biotechnology
  732. ViralClear Pharmaceuticals
  733. Visterra
  734. Viva Biotech
  735. Voyager Therapeutics
  736. Washington University
  737. Washington University School of Medicine
  738. Westlake Pharmaceuticals Services
  739. Westlake Therapeutics
  740. Wisconsin Alumni Research Foundation
  741. Worg Pharmaceuticals
  742. WuXi AppTec
  743. WuXi Biologics
  744. WuXi STA
  745. Wyss Institute
  746. XBiotech
  747. xCella Biosciences
  748. X-Chem
  749. Xencor
  750. XOMA
  751. Y- Biologics
  752. Yale Cancer Center
  753. Yangyang
  754. YenZym Antibodies
  755. Yinuoke
  756. Ymmunobio
  757. YUMAB
  758. Yurogen Biosystems
  759. Zai Lab
  760. Zebra Biologics
  761. Zhejiang Doer Biologics
  762. Zhejiang Teruisi Biopharmaceuticals
  763. Zoetis
  764. ZoonBio Biotechnology
  765. Zumutor Biologics
  766. Zydus
  767. Zymeworks

Source 1: https://www.pharmasalmanac.com/articles/what-do-you-consider-the-biggest-challenge-that-the-pharma/biopharma-industry-currently-faces
Source 2: https://www.sciencedirect.com/science/article/pii/S2049080114000624

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com